Institution
University of Virginia
Education•Charlottesville, Virginia, United States•
About: University of Virginia is a education organization based out in Charlottesville, Virginia, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 52543 authors who have published 113268 publications receiving 5220506 citations. The organization is also known as: U of V & UVa.
Topics: Population, Poison control, Galaxy, Context (language use), Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The theoretical basis for modeling univariate traffic condition data streams as seasonal autoregressive integrated moving average processes as well as empirical results using actual intelligent transportation system data are presented and found to be consistent with the theoretical hypothesis.
Abstract: This article presents the theoretical basis for modeling univariate traffic condition data streams as seasonal autoregressive integrated moving average processes. This foundation rests on the Wold decomposition theorem and on the assertion that a one-week lagged first seasonal difference applied to discrete interval traffic condition data will yield a weakly stationary transformation. Moreover, empirical results using actual intelligent transportation system data are presented and found to be consistent with the theoretical hypothesis. Conclusions are given on the implications of these assertions and findings relative to ongoing intelligent transportation systems research, deployment, and operations.
1,406 citations
••
University of Virginia1, Memorial Sloan Kettering Cancer Center2, Washington University in St. Louis3, Fred Hutchinson Cancer Research Center4, National Institutes of Health5, Harvard University6, Novartis7, Seattle Children's8, University of Pennsylvania9, University College London10, Center for International Blood and Marrow Transplant Research11, University of Miami12, University of Texas MD Anderson Cancer Center13
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
1,403 citations
••
University of Texas MD Anderson Cancer Center1, Cornell University2, Rutgers University3, Barts Health NHS Trust4, University of Wisconsin-Madison5, Jagiellonian University6, Stanford University7, University of Virginia8, Hofstra University9, University of Manchester10, University of Ulm11, Ludwig Maximilian University of Munich12, Medical University of Warsaw13, University of Southampton14, Oregon Health & Science University15, Ohio State University16
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Abstract: rolled into two groups: those who had previously received at least 2 cycles of bor - tezomib therapy and those who had received less than 2 complete cycles of bortezo - mib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression- free survival, overall survival, and safety. RESULTS The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytope - nia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treat - ment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval (CI), 15.8 to not reached), the estimated median progression- free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
1,389 citations
••
TL;DR: There is now compelling evidence that a full understanding of VSMC behavior in Atherosclerosis is critical to identify therapeutic targets to both prevent and treat atherosclerosis.
Abstract: The historical view of vascular smooth muscle cells (VSMCs) in atherosclerosis is that aberrant proliferation of VSMCs promotes plaque formation, but that VSMCs in advanced plaques are entirely beneficial, for example preventing rupture of the fibrous cap. However, this view has been based on ideas that there is a homogenous population of VSMCs within the plaque, that can be identified separate from other plaque cells (particularly macrophages) using standard VSMC and macrophage immunohistochemical markers. More recent genetic lineage tracing studies have shown that VSMC phenotypic switching results in less-differentiated forms that lack VSMC markers including macrophage-like cells, and this switching directly promotes atherosclerosis. In addition, VSMC proliferation may be beneficial throughout atherogenesis, and not just in advanced lesions, whereas VSMC apoptosis, cell senescence, and VSMC-derived macrophage-like cells may promote inflammation. We review the effect of embryological origin on VSMC behavior in atherosclerosis, the role, regulation and consequences of phenotypic switching, the evidence for different origins of VSMCs, and the role of individual processes that VSMCs undergo in atherosclerosis in regard to plaque formation and the structure of advanced lesions. We think there is now compelling evidence that a full understanding of VSMC behavior in atherosclerosis is critical to identify therapeutic targets to both prevent and treat atherosclerosis.
1,389 citations
••
TL;DR: In this article, a formal integration of standard volatility models with market microstructure variables to allow for a more comprehensive empirical investigation of the fundamental determinants behind the volatility clustering phenomenon is presented.
1,388 citations
Authors
Showing all 53083 results
Name | H-index | Papers | Citations |
---|---|---|---|
Joan Massagué | 189 | 408 | 149951 |
Michael Rutter | 188 | 676 | 151592 |
Gordon B. Mills | 187 | 1273 | 186451 |
Ralph Weissleder | 184 | 1160 | 142508 |
Gonçalo R. Abecasis | 179 | 595 | 230323 |
Jie Zhang | 178 | 4857 | 221720 |
John R. Yates | 177 | 1036 | 129029 |
John A. Rogers | 177 | 1341 | 127390 |
Bradley Cox | 169 | 2150 | 156200 |
Mika Kivimäki | 166 | 1515 | 141468 |
Hongfang Liu | 166 | 2356 | 156290 |
Carl W. Cotman | 165 | 809 | 105323 |
Ralph A. DeFronzo | 160 | 759 | 132993 |
Elio Riboli | 158 | 1136 | 110499 |
Dan R. Littman | 157 | 426 | 107164 |